Seeking Alpha

Coronado Biosciences, Inc. (CNDO)

  • Mon, Apr. 20, 12:45 PM
    • Micro cap Coronado Biosciences (CNDO -2.8%), down as much as 19% today before recovering, disclosed in a regulatory filing that it terminated development of its Trichuris suis ova program for the treatment of pediatric patients with autism spectrum disorder after a preliminary data analysis from a Phase 2a trial failed to demonstrate any signal of activity.
    | Comment!
  • Mon, Apr. 20, 9:17 AM
    | Comment!
  • Wed, Apr. 8, 1:05 PM
    • The following companies are extended at least 30% above their 50-day moving averages, trade at least 500K shares per day, have market caps less than $500M and have poor fundamentals:
    • (CAPN -7.6%)(AMRN +4.1%)(NYMX +3.6%)(CRMD -1.2%)(CNDO +6.8%)(ADXS +13.1%)(AXN +3.6%)(DRRX +4.9%)(CYTX -1.9%)(AVEO +2.6%)(RIGL +1.8%)(NVGN +10.5%)
    • The list is not meant to provide Buy/Sell recommendations. It is a group of stocks that may warrant further research by individual investors.
  • Thu, Apr. 2, 8:12 AM
    • Coronado Biosciences (NASDAQ:CNDO) forms a new subsidiary, DiaVax Biosciences, to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV) infection. CMV affects almost everyone. It is typically asymptomatic in healthy people, but can cause severe problems in those with weakened or undeveloped immune systems.
    • DiaVax secured the worldwide rights to two T-cell immunotherapeutic vaccines from City of Hope for controlling CMV in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients. The vaccines, known as Triplex and PepVax, are expected to enter Phase 2 development later this year. DiaVax also has an option with City of Hope for exclusive global rights to Pentamer, a universal immunotherapeutic vaccine being developed for the prevention of CMV transmission in utero. City of Hope is eligible to receive milestones and other payments of $100M+ if the three product candidates are successfully developed and commercialized.
    | Comment!
  • Tue, Mar. 31, 12:45 PM
    | Comment!
  • Thu, Mar. 19, 1:41 PM
    • Thinly-traded micro cap Coronado Biosciences (CNDO +39.8%) jumps on a whopping 56x surge in volume in response to its announcement that it has formed a new company, Mustang Therapeutics, to develop and commercialize a portfolio of CAR-T cells developed by researchers at City of Hope located at Duarte, CA.
    • The deal is valued in excess of $40M based on an upfront payment and milestones. Clinical trials to evaluate the first two CAR-T cells in humans will commence at City of Hope later this year.
    | Comment!
  • Thu, Mar. 19, 1:29 PM
    • Investors show some love for CAR-T-related stocks today. Drugs based on Chimeric Antigen Receptor technology are the "next big things" in cancer treatment. Early data show impressive results in certain blood cancers.
    • Newcomer Cellectis (Pending:CLLS) should debut shortly.
    • Related tickers: (JUNO +14.8%)(KITE +14.9%)(BLUE +5.2%)(BLCM +7.7%)(ZIOP +4.6%)(CNDO +40.1%)
  • Thu, Mar. 19, 12:47 PM
  • Thu, Mar. 19, 9:50 AM
    • Coronado Biosciences (CNDO +41.9%) executes an exclusive licence agreement with Suzhou, China-based NeuPharma to develop and commercialize novel the pre-clinical stage irreversible third generation EGFR inhibitors on a global basis outside of certain Asian countries.
    • Under the terms of the agreement, NeuPharm will receive an upfront payment, development- and sales-based milestones and tiered single-digit royalties on net sales. Specific financial terms are not disclosed.
    • The epidermal growth factor receptor (EGFR) is a cell surface protein, specifically a transmembrane tyrosine kinase receptor, that plays a key role in regulating cell division and death. It belongs to the human epidermal growth factor receptor (HER) family and is a target of anti-cancer and anti-inflammatory therapies.
    • Commercially available EGFR inhibitors are AstraZeneca's Iressa (gefitinib) and Caprelsa (vandetanib), Roche's Tarceva (erlotinib), Bristol-Myers Squibb's Erbitux (cetuximab), Glaxo's Tykerb (lapatinib) and Amgen's Vectibix (panitumumab).
    | Comment!
  • Thu, Mar. 19, 9:16 AM
    | Comment!
  • Mon, Mar. 16, 9:59 AM
    • Coranado Biosciences (CNDO +2.3%) Q4 results: Revenues: $0; R&D Expense: $1.8M (-72.7%); SG&A: $3.2M (+6.7%); Operating Loss: ($5M) (+47.4%); Net Loss: ($3.7M) (+62.2%); Loss Per Share: ($0.10) (+63.0%).
    • FY2014 results: Revenues: $0; R&D Expense: $10.2M (-60.3%); SG&A: $10.4M (+3.0%); Operating Loss: ($20.7M) (+42.2%); Net Loss: ($20.4M) (+45.2%); Loss Per Share: ($0.56) (+54.1%); Quick Assets: $69.8M (-29.8%).
    • No guidance given.
    | Comment!
  • Mon, Mar. 16, 7:36 AM
    | Comment!
  • Wed, Mar. 4, 12:45 PM
    | Comment!
  • Wed, Mar. 4, 9:50 AM
    • Thinly-traded micro cap Coronado Biosciences (CNDO +15.8%) jumps in early trading in response to its announcement of the signing of a collaboration agreement with a researcher at the Dana-Farber Cancer Institute to develop novel immuno-oncology antibodies for blood cancers.
    • The company will form a new subsidiary, Checkpoint Therapeutics, to develop a portfolio of antibodies produced in the laboratory of Dr. Wayne Marasco, M.D. at Dana-Farber, including PD-L1, GITR and CAIX. Clinical trials are expected to commence in H2 2016.
    • Dr. Marasco will chair the Scientific Advisory Board of the company and Checkpoint will pay Dana-Farber an undisclosed upfront licensing fee, development and sales milestones and royalties on net sales.
    • In connection with the Dana-Farber partnership, Checkpoint inks a collaboration deal with TG Therapeutics (TGTX +2.3%) to develop and commercialize anti-PD-L1 and anti-GITR in hematologic malignancies. Both programs are in preclinical development. Checkpoint retains the rights to develop and commercialize both antibodies in solid tumors. Under the terms of the agreement, TG will pay Checkpoint an disclosed upfront license fee, development and sales milestones and tiered single-digit royalties on net sales.
    | Comment!
  • Wed, Mar. 4, 9:13 AM
  • Tue, Mar. 3, 8:50 AM
    • Coronado Biosciences (NASDAQ:CNDO) closes a private placement of a $10M promissory note. The debt matures in 36 months but may extend to 42 months under certain conditions. No principal will be due for the first 24 months (or 30 if the maturity date is extended). Thereafter, 1/12 of the principal will be due each month. The coupon rate is 8% payable quarterly.
    • Proceeds will fund the acquisition of medical technologies and products in addition to the creation of subsidiaries to advance them.
    | Comment!
Visit Seeking Alpha's
CNDO vs. ETF Alternatives
Company Description
Coronado Biosciences Inc is a biopharmaceutical company. The Company is engaged in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, namely CNDO-201 or Trichuris suis ova and CNDO-109.
Sector: Healthcare
Industry: Biotechnology
Country: United States